Trans Genic Inc.

Tokyo Stock Exchange 2342.T

Trans Genic Inc. Cash and Short-Term Investments for the year ending March 31, 2024: USD 16.37 M

Trans Genic Inc. Cash and Short-Term Investments is USD 16.37 M for the year ending March 31, 2024, a -37.12% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • Trans Genic Inc. Cash and Short-Term Investments for the year ending March 31, 2023 was USD 26.04 M, a -31.46% change year over year.
  • Trans Genic Inc. Cash and Short-Term Investments for the year ending March 31, 2022 was USD 37.99 M, a 38.84% change year over year.
  • Trans Genic Inc. Cash and Short-Term Investments for the year ending March 31, 2021 was USD 27.36 M, a 792.90% change year over year.
  • Trans Genic Inc. Cash and Short-Term Investments for the year ending March 31, 2020 was USD 3.06 M.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
SV Wall Street
Tokyo Stock Exchange: 2342.T

Trans Genic Inc.

CEO Kenji Fukunaga
IPO Date Dec. 10, 2002
Location Japan
Headquarters 2-3-36 Tenjin
Employees 236
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Trans Genic Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment Business segments. The company provides glycan synthesis and analysis services; non-clinical studies for pharmaceuticals, foods, cosmetics, chemical substances, etc., as well as various safety tests for foods, and pharmaceutical agents; and support for bioequivalence test, including clinical trials, pharmacokinetic measurements, and the preparation of clinical trial reports; as well as hospital support services. It also offers drug efficiency and pharmacological test and safety studies; sugar chain analysis and synthesis services; advice and support services, including M&A, business revitalization, business succession services; and contract production services, such as genetically modified mice, antibodies, protein hypers, and expressing cells, as well as sells mouse-related products and mouse models, and research reagents. The company was formerly known as Kumamoto Immunochemical Laboratories Inc. and changed its name to Trans Genic Inc. in April 2000. Trans Genic Inc. was incorporated in 1998 and is headquartered in Fukuoka City, Japan.

StockViz Staff

January 31, 2025

Any question? Send us an email